Skip to main content
SpringerLink
Log in

Human Volunteer Studies — Safety Considerations in an Era of Highly Active Biological Agents

Lessons from the TeGenero Tragedy

  • Commentary
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stein C. Managing risk in healthy subjects participating in clinical research. Clin Pharmacol Ther 2003; 74: 511–2

    Article  PubMed  Google Scholar 

  2. Darragh A, Kenny M, Lambe R, et al. Sudden death of a volunteer. Lancet 1985; I: 93–4

    Article  Google Scholar 

  3. Kolata G. The death of a research subject. Hastings Cent Rep 1980; 10 (4): 5–6

    Article  PubMed  CAS  Google Scholar 

  4. Trigg C, Freestone D, Lee T, et al. Death of a healthy student volunteer in a US research study: lessons for bronchoscopic practice. Int J Pharm Med 1998; 12: 151–3

    Google Scholar 

  5. Snell N. Death of a healthy research subject after an inhalation study: old lessons to be re-learned. Int J Pharm Med 2001; 15: 167–8

    Google Scholar 

  6. Cottington E, LaMantia C, Stabler S, et al. Adverse event associated with methionine loading test. Arterioscer Thromb Vasc Biol 2002; 22: 1046–50

    Article  CAS  Google Scholar 

  7. Raper S, Chirmule N, Lee F, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148–58

    Article  PubMed  CAS  Google Scholar 

  8. Cardon P, Dommer F, Trumble R. Injuries to research subjects. N Engl J Med 1976; 295: 650–4

    Article  PubMed  CAS  Google Scholar 

  9. Zarafonetis C, Riley P, Willis P, et al. Clinically significant adverse effects in a phase I testing program. Clin Pharmacol Ther 1978; 21: 127–32

    Google Scholar 

  10. Royle J, Snell E. Medical research on normal volunteers. Br J Clin Pharmacol 1986; 21: 548–9

    Article  PubMed  CAS  Google Scholar 

  11. Williams R. First time in man studies: an academic perspective. J Clin Pharmacol 1990; 30: 210–2

    Google Scholar 

  12. Suntharalingam G, Perry M, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018–28

    Article  PubMed  CAS  Google Scholar 

  13. Beyersdorf N, Hanke T, Kerkau T, et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 2005; 64 Suppl. 4: iv91–5

    Google Scholar 

  14. Deer B. Elephant man given drug ‘too quickly’. Sunday Times 2006 Sep 24 [online]. Available from URL: http://www.timesonline.co.uk [Accessed 2006 Oct 5]

  15. Bhattacharya S, Coghlan A. One drug, six men, disaster. New Sci 2006; 189 (2544): 10–1

    PubMed  Google Scholar 

  16. Ghosh P. Doubt cast over drug trial safety [online]. Available from URL: http://news.bbc.co.uk/1/hi/health/4989810.stm [Accessed 2006 Oct 5]

  17. Mayor S. Severe adverse reactions prompt call for trial design changes. BMJ 2006; 332: 683

    Article  PubMed  Google Scholar 

  18. Sheridan C. TeGenero fiasco prompts regulatory rethink. Nat Biotech 2006; 24: 475–6

    Article  CAS  Google Scholar 

  19. Phan G, Haworth L, Duray P, et al. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression [abstract 3424]. Proc Am Soc Clin Oncol 2003; 22

    Google Scholar 

  20. Schneider C, Kalinke U, Lower J. TGN1412: a regulator’s perspective. Nat Biotech 2006; 24: 493–6

    Article  CAS  Google Scholar 

  21. Investigations into adverse incidents during clinical trials of TGN1412 [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?.IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2023822&ssTargetNodeId=389 [Accessed 2006 Oct 5]

  22. The Academy of Medical Sciences. Testing antibody therapies: position paper [online]. Available from URL: http://www.acmedsci.ac.uk [Accessed 2006 Oct 5]

  23. Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. ATLA 2006; 34: 225–39

    PubMed  CAS  Google Scholar 

  24. Expert Scientific Group on Phase One Clinical Trials: a consultation. Interim report: 20th July 2006 [online]. Available from URL: http://www. dh.gov.uk/Consultations/ClosedConsultations/ClosedConsultationsArticle/fs/ en?.CONTENT_ID=4139038&chk=Heo5Fe [Accessed 2006 Oct 5]

  25. Early Stage Clinical Trial Taskforce: Joint ABPI/BIA report. Final Draft 3-7-06 [online]. Available from URL: http://www.iir-events.com/IIR-conf/PTI/DocumentView.aspx?.EventID=199&DocumentID=504 [Accessed 2006 Oct 5]

  26. National Patient Safety Agency: Central Office for Research Ethics Committees. Letter to Chairs of all NHS Research Ethics Committees in the UK. Dated 2006 Apr 28

    Google Scholar 

  27. Warrington S. Clinical pharmacology in the headlines: reflections on the TGN1412 trial. pA2 (Newsletter of the British Pharmacological Society) 2006; 4 (2): 8–9

    Google Scholar 

  28. Zammit F. Letter. New Sci 2006; 191 (2565): 21

    Article  Google Scholar 

  29. Levy O, Suter E, Miller R, et al. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108: 1284–90

    Article  PubMed  CAS  Google Scholar 

  30. Geddes L. What does the future hold for drug trial victims? New Sci 2006; 191 (2564): 10

    Article  Google Scholar 

Download references

Acknowledgements

The opinions expressed in this article are those of the author and not necessarily those of his employers.

No sources of funding were used to assist in the preparation of this commentary. The author has no conflicts of interest that are directly relevant to the content of this commentary.

Author information

Authors and Affiliations

  1. Experimental Medicine, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, LE 11 5RH, UK

    Noel J. C. Snell

Authors
  1. Noel J. C. Snell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noel J. C. Snell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Snell, N.J.C. Human Volunteer Studies — Safety Considerations in an Era of Highly Active Biological Agents. Int J Pharm Med 20, 293–296 (2006). https://doi.org/10.2165/00124363-200620050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200620050-00002

Keywords

Search

Navigation